Citi Appointed Depositary Bank for BeiGene, Ltd.’s Sponsored ADR Program
February 08 2016 - 6:53PM
Business Wire
Citi’s Issuer Services business, acting through Citibank N.A.,
has been appointed by BeiGene, Ltd., a clinical-stage
biopharmaceutical company focused on developing molecularly
targeted and immuno-oncological drugs for the treatment of cancer,
as the depositary bank for its American Depositary Receipt (ADR)
program.
BeiGene’s ADR program was established through its initial public
offering. The ADRs are listed on the NASDAQ under the symbol
“BGNE.” Each ADR represents 13 ordinary shares. As a single-listed
ADR program, the underlying ordinary shares are not listed or
publicly traded in the issuer’s home market.
“Citi is proud to be selected as depositary bank for BeiGene’s
ADR program,” said Dirk Jones, Head of Global Issuer Services at
Citi. “Citi is committed to providing BeiGene and its investors
with the highest quality ADR services.”
Citi is a leading provider of depositary receipt services. With
depositary receipt programs in 56 markets, spanning equity and
fixed-income products, Citi leverages its global network to provide
cross-border capital market access to issuers, intermediaries and
investors.
For more information about Citi’s Depositary Receipt Services,
please visit www.citi.com/dr.
Citi
Citi, the leading global bank, has approximately 200 million
customer accounts and does business in more than 160 countries and
jurisdictions. Citi provides consumers, corporations, governments
and institutions with a broad range of financial products and
services, including consumer banking and credit, corporate and
investment banking, securities brokerage, transaction services, and
wealth management.
Additional information may be found at www.citigroup.com |
Twitter: @Citi | YouTube: www.youtube.com/citi | Blog:
http://blog.citigroup.com | Facebook: www.facebook.com/citi |
LinkedIn: www.linkedin.com/company/citi
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160208006433/en/
CitiRobert Julavits, 212-816-8020robert.w.julavits@citi.com
Citigroup (NYSE:C)
Historical Stock Chart
From Aug 2024 to Sep 2024
Citigroup (NYSE:C)
Historical Stock Chart
From Sep 2023 to Sep 2024